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CYLD is a tumour-suppressor gene that is mutated in
a benign skin tumour syndrome called cylindromatosis.
The CYLD gene product is a deubiquitinating enzyme that
was shown to regulate cell proliferation, cell survival and
inﬂammatory responses, mainly through inhibiting NF-jB
signalling. Here we show that CYLD controls cell growth
and division at the G1/S-phase as well as cytokinesis by
associating with a-tubulin and microtubules through its
CAP-Gly domains. Translocation of activated CYLD to the
perinuclear region of the cell is achieved by an inhibitory
interaction of CYLD with histone deacetylase-6 (HDAC6)
leading to an increase in the levels of acetylated a-tubulin
around the nucleus. This facilitates the interaction of
CYLD with Bcl-3, leading to a signiﬁcant delay in the G1-to-
S-phase transition. Finally, CYLD also interacts with HDAC6
in the midbody where it regulates the rate of cytokinesis in a
deubiquitinase-independent manner. Altogether these
results identify a mechanism by which CYLD regulates
cell proliferation at distinct cell-cycle phases.
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Introduction
Familial cylindromatosis is characterized by formation of
multiple benign tumours originating from skin (Bignell
et al, 2002). The tumour syndrome is caused by the loss of
both CYLD alleles. The CYLD gene encodes a deubiquitinat-
ing enzyme, which removes lysine 48- or lysine 63-linked
polyubiquitin chains from target proteins (Massoumi and
Paus, 2007). Depending on the cellular context CYLD has
been shown to negatively regulate NF-kB and/or JNK-signal-
ling pathways resulting in suppression of cell proliferation
and survival (Brummelkamp et al, 2003; Kovalenko et al,
2003; Trompouki et al, 2003; Reiley et al, 2004). The mechan-
ism by which CYLD exerts its tumour-suppressor function
in vivo has been analyzed in CYLD-null mice, which are
highly susceptible to chemically induced skin tumours. The
increased tumour incidence was attributed to the loss of
an inhibitory interaction between CYLD and the proto-onco-
gene Bcl-3. The association of CYLD with Bcl-3, which results
from activation and subsequent perinuclear translocation
of the protein, leads to the removal of a lysine 63-linked
ubiquitin chain from Bcl-3, which in turn inhibits the nuclear
translocation and activity of Bcl-3 (Massoumi et al, 2006). In
the absence of CYLD, Bcl-3 is able to translocate into the
nucleus where it forms a complex with the NF-kB p50 and
p52 isoforms. This results in activation of the cyclin-D1
promoter and increased proliferation and tumour growth
(Massoumi et al, 2006). It is not clear, however, how CYLD
translocates to the perinuclear region to capture Bcl-3 and
whether this is the only mechanism by which CYLD regulates
tumour cell proliferation.
In addition to the C-terminal ubiquitin C-terminal hydro-
lase (UCH) domain, which executes the removal of ubiquitin
chains, CYLD contains three cytoskeleton-associated protein-
glycine-conserved (CAP-Gly) domains in the N-terminal por-
tion of the protein. The exact function of CAP-Gly domains is
not known, but their presence in various microtubule (MT)-
binding proteins suggests that they enable binding to MTs
(Riehemann and Sorg, 1993; Pierre et al, 1994; Bateman et al,
2002). The third CAP-Gly domain (CAP-Gly3) of CYLD has
recently been shown to associate directly with the proline-
rich sequences of NEMO/IKKg, a pseudokinase, which
together with IKKa and IKKb triggers TNF-receptor-mediated
NF-kB activation (Bateman et al, 2002). Interestingly, this
CAP-Gly domain (Saito et al, 2004) differs structurally from
the ﬁrst two CAP-Gly domains (CAP-Gly1 and CAP-Gly2),
which have been recently shown to associate directly with
tubulin and promote tubulin polymerization (Gao et al,
2008). Whether the CAP-Gly domains in CYLD have any
additional function besides tubulin binding is not known.
The stability of MTs is accompanied by post-translational
modiﬁcations of a-tubulin such as acetylation, which usually
occurs after MT assembly (Westermann and Weber, 2003).
The level of a-tubulin acetylation in cells is accurately
adjusted by the activities of tubulin acetyltransferases and
deacetylases, which catalyze the acetylation and deacetylation
of a-tubulin, respectively. Elp3 was identiﬁed very recently as
a-tubulin acetyltransferase in neuronal cells (Creppe et al,
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1312009), while HDAC6 (histone deacetylase-6) and SIRT2 (the
Silent Information Regulator Type-2) have been shown to
deacetylate a-tubulin (Hubbert et al, 2002; North et al, 2003).
HDAC6 contains two intact HDAC catalytic domains, which
execute deacetylation of a-tubulin (Zhang et al, 2006; Zou
et al, 2006; Boyault et al, 2007a), and a ubiquitin-binding
zinc-ﬁnger domain, which enables binding to ubiquitinated
proteins (Seigneurin-Berny et al, 2001; Hook et al, 2002;
Boyault et al, 2006). Even though HDAC6 contains both
intrinsic nuclear import and export signals, it is mainly
found in the cytoplasm (Verdel et al, 2000) where it localizes
around the nucleus or at the leading edge of migrating cells
(Hubbert et al, 2002). HDAC6 has also been shown to have a
scaffold role for lymphocyte migration independent of its
activity (Cabrero et al, 2006). Furthermore, the activity of
HDAC6 promotes cell motility by regulation of membrane
rufﬂe formation, macropinocytosis, and actin remodelling
(Gao et al, 2007). Besides regulating cell motility, HDAC6 is
also involved in the response of cells to various types of stress
stimuli (Boyault et al, 2007b; Kawaguchi et al, 2003; Kwon
et al, 2007), immune synapse organization, and the antigen-
speciﬁc reorientation of the microtubule organizing center
(MTOC) (Serrador et al, 2004).
In this paper we addressed the role of CYLD and speciﬁ-
cally its N-terminal CAP-Gly domains in the regulation of cell
proliferation both in primary keratinocytes and malignant
melanoma cells. We found that CYLD associates with MTs
and colocalizes primarily with acetylated tubulin. Activation
of CYLD increases the levels of acetylated a-tubulin by
interaction of the N-terminal domain of CYLD with the
catalytic site of HDAC6. This interaction inhibits HDAC6-
mediated tubulin deacetylation, allowing CYLD to translocate
to the perinuclear region. Perinuclear localized CYLD induces
a delay in the G1/S transition phase of the cell cycle through a
Bcl-3-mediated pathway. In addition, CYLD is found in the
midbody where it also associates with HDAC6 and regulates
the rate of cytokinesis.
Results
Interaction of CYLD with tubulin and MT
We have earlier shown that UV or TPA treatment of primary
mouse keratinocytes triggers perinuclear accumulation of
CYLD, which correlates with its ability to interact with its
downstream targets (Massoumi et al, 2006). The present
work aimed at understanding whether an MT-dependent
mechanism was involved in the translocation of CYLD.
To explore this we used primary mouse keratinocytes, pri-
mary human melanocytes, and different human malignant
melanoma cells. Analysis of subcellular localization of CYLD
in primary mouse keratinocytes revealed that TPA treatment
caused a robust increase in perinuclear, acetylated a-tubulin
(Figure 1A), and a colocalization of CYLD with acetylated
MTs (Figure 1A). However, we could observe only partial
colocalization of CYLD with tyrosinated a-tubulin in the
cytoplasm (Supplementary Figure S1A). Interestingly, all
melanoma cell lines we have tested so far lack detectable
CYLD expression (Massoumi et al, 2009). Therefore, we
restored CYLD expression in two different malignant mela-
noma cell lines, MEL and Juso melanoma cells (Rothhammer
et al, 2005), by lentivirally transducing full-length, EGFP-
tagged CYLD cDNA. In melanoma cells EGFP–CYLD was
constitutively present in the perinuclear region where it
colocalized with acetylated tubulin (Supplementary Figure
S1B, lower panels), while no colocalization with peripheral,
tyrosinated a-tubulin could be observed (Supplementary
Figure S1B, upper panels). These results suggest that CYLD
colocalizes mainly with acetylated MTs in the perinuclear
region, and this localization is constitutive in CYLD-trans-
duced melanoma cells, whereas in primary mouse keratino-
cytes or primary human melanocytes (Supplementary Figure
S1C) it is induced after TPA treatment or exposure to UV light.
A constitutive perinuclear localization of CYLD has also been
reported for other tumour cell lines (Regamey et al, 2003).
Next we investigated whether CYLD, through its CAP-Gly
domains, can interact with MTs. Immunoprecipitation of
endogenous CYLD in melanocytes revealed an interaction
with a-tubulin (Figure 1B). The interaction of CYLD with
tubulin was conﬁrmed by reverse immunoprecipitation of a-
tubulin and subsequent immunoblotting against CYLD in
melanocytes (Figure 1B) and in primary mouse keratinocytes
(Figure 1C). As expected, immunoprecipitation of EGFP–
CYLD from melanoma cells co-precipitated a-tubulin
(Supplementary Figure S2A). Furthermore, exposure of ker-
atinocytes (Figure 1C) or melanocytes (Figure 1D) to noco-
dazole, which depolymerises MTs, induced rapid dissociation
of CYLD from MTs, suggesting that CYLD associates with
polymerised tubulin. In contrast, the association of drug- and
cold-resistant, MT-associated protein-4 (MAP4) (Webster and
Bratcher, 2006), and tubulin was unaffected in the presence
of nocodazole (Figure 1C). To conﬁrm the association of
CYLD with polymerised MTs, we performed MT-co-sedimen-
tation assays using in vitro translated CYLD and in vitro
assembled MTs. The majority of the CYLD protein was
found in the heavy pellet fraction indicating that CYLD
binds to polymerised MTs (Figure 1E, upper panels). To
control the speciﬁcity of our assay, we used in vitro translated
Bax, which does not bind MTs. As expected, Bax was
exclusively found in the supernatant fraction both in the
presence and absence of MTs (Figure 1E, lower panels).
To identify the interaction site on CYLD for a-tubulin
binding, we transfected HeLa cells with cDNAs encoding
FLAG-tagged, full-length CYLD or FLAG-tagged, CYLD-dele-
tion mutants (Supplementary Figure S2B). FLAG pull-down
assays conﬁrmed the interaction between CYLD and a-tubu-
lin, and further showed that the ﬁrst and the second, but
neither the third CAP-Gly nor the UCH, domain of CYLD
interacted with a-tubulin (Figure 1F). Together these results
indicate that CYLD associates preferentially with polymerised
tubulin and that the ﬁrst and second CAP-Gly domains of
CYLD mediate the binding to MTs both in vitro and in vivo.
CYLD induces acetylation of a-tubulin and stabilization
of MTs
As CYLD associates with MTs and colocalizes speciﬁcally
with acetylated MTs, we hypothesized that CYLD might
directly regulate a-tubulin acetylation to control its own
localization. To investigate this we analysed the levels of
acetylated tubulin in primary mouse keratinocytes. Both
Cyld
þ/þ and Cyld
 /  keratinocytes contained low levels
of acetylated tubulin (Figure 2A). While TPA treatment
did not change the total levels of a-tubulin, it increased
the levels of acetylated a-tubulin in Cyld
þ/þ keratinocytes
but not in Cyld
 /  keratinocytes. (Figure 2A). This increase
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acetylated a-tubulin (Figure 2B). Importantly, re-expression
of CYLD in Cyld
 /  keratinocytes restored the ability of these
cells to respond to TPA by increasing the levels of acetylated
a-tubulin (Figure 2C). Reconstitution of melanoma cells with
EGFP–CYLD induced an almost sixfold increase in the levels
of acetylated a-tubulin (Figure 2D). Furthermore, transient
transfection of melanoma cells with increasing concentra-
tions of the EGFP–CYLD cDNA showed direct correlation
between levels of CYLD expression and acetylated a-tubulin
(Figure 2E and F). These results suggest that CYLD increases
the level of acetylated a-tubulin in both TPA-stimulated
keratinocytes as well as in untreated melanoma cells.
To determine whether the increase in a-tubulin acetylation
depends on the deubiquitinase activity of CYLD, we
transduced melanoma cells with catalytically inactive CYLD
(CYLD
C/S). CYLD
C/S increased the acetylation of a-tubulin
to the same extent as with full-length, wild-type CYLD
(Figure 2G), indicating that the UCH domain of CYLD is not
required for a-tubulin acetylation.
To investigate whether the association of CYLD with MTs
inﬂuences their dynamic properties, we treated melanoma
cells with nocodazole and monitored MT re-growth after
nocodazole washout. Polymerised MT ﬁbres in CYLD-expres-
sing melanoma cells were evident already 10min after the
washout (Figure 2H) and acetylated a-tubulin after 30min
(Figure 2I). In EGFP-expressing melanoma cells, however,
MT ﬁbres were detected only 30min after nocodazole
washout (Figure 2H), and we failed to observe acetylation
of a-tubulin even 2h after nocodazole washout (Figure 2I).
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Figure 1 Interaction of CYLD with tubulin and microtubules. (A) The confocal plane of keratinocytes stained for acetylated a-tubulin and
CYLD in the absence or presence of 100nM TPA for 30min. The ﬂuorescence intensity linescan proﬁle was generated through the merged
image and demonstrates the dependence of the two ﬂuorescent populations. (B) Immunoprecipitation of endogenous CYLD (left panels),
a-tubulin (right panels), or control antibody (IgG) from human primary melanocytes, and immunoblotting against a-tubulin or CYLD. The
lysate shows equal amount of protein used for immunoprecipitation. (C) Immunoprecipitation of a-tubulin from primary mouse keratinocytes
in the absence or presence of nocodazole (10mM for 60min), and immunoblotting against a-tubulin, CYLD, or MAP4. The lysate (lower panel)
shows equal amount of protein used for immunoprecipitation. (D) Immunoprecipitation of endogenous CYLD from human melanocytes in the
absence or presence of nocodazole (10 or 30mM for 60min), and immunoblotting against a-tubulin or CYLD. The lysate (lower panel) shows
equal amount of protein used for immunoprecipitation. (E) Microtubule co-sedimentation assay using in vitro translated,
35S-labelled CYLD
(upper panel) or Bax (lower panel) in the presence or absence of taxol-stabilized microtubules. S: Supernatant and P: Pellet fraction of samples
separated with SDS–PAGE after which the presence of
35S-labelled CYLD or Bax was detected by ﬂuorography. (F) FLAG immunoprecipitates of
HeLa cells transiently transfected with different FLAG-tagged deletion mutants of CYLD (1.0mg) and analysed by immunoblotting with
antibodies against a-tubulin.
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and also inﬂuences the polymerization rate of MTs.
Next, we analysed the effect of CYLD on MT depolymer-
isation by treating EGFP–CYLD- or EGFP-expressing melano-
ma cells with increasing concentrations of nocodazole
and found that in the presence of CYLD, MTs began to
partially depolymerise at 5-mM concentrations (with some
MT ﬁbres still detectable) (Supplementary Figure S3A). Total
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Figure 2 CYLD increases the level of acetylated a-tubulin. (A) Analysis of the levels (left panels) and quantiﬁcation (right panel) of acetylated
a-tubulin and total tubulin in Cyld
þ/þ and Cyld
 /  keratinocytes treated with TPA (15, 30 and 60min). (B) Immunoprecipitation of
endogenous CYLD from keratinocytes treated with 100nM TPA and immunoblotting against acetylated-a-tubulin or CYLD. The lysate (lower
panel) shows equal amount of protein used for immunoprecipitation. (C) Analysis of the levels of acetylated a-tubulin and total tubulin in
untreated or TPA-treated (30min) Cyld
 /  keratinocytes (control) or Cyld
 /  keratinocytes transiently transfected with full-length-CYLD for
48h. (D) Analysis of the levels of acetylated a-tubulin, total tubulin, or CYLD in two different melanoma cell lines (MEL Im and Juso) infected
with mock, EGFP, or EGFP–CYLD lentivirus (1 10
5 IU) for 24h. The medium was replaced two times before the cells were lysed and used for
immunoblotting against a-tubulin, total tubulin, or CYLD. (E) Analysis of the levels of acetylated a-tubulin, total tubulin, and CYLD in
melanoma cells (Juso) transiently transfected with increasing concentrations of EGFP–CYLD cDNA. (F) The confocal plane of human
malignant melanoma cell line (Juso) transiently transfected with 1.0mg EGFP–CYLD (green) for 24h and stained for acetylated a-tubulin (red).
The asterisk indicates cells lacking CYLD expression. (G) Analysis of the levels of acetylated a-tubulin and total tubulin in melanoma cells
transduced with 1 10
5 IU of HA, HA–CYLD, or the catalytically inactive mutant HA–CYLD
C/S lentivirus for 24h. The medium was replaced
two times before the cells were lysed and used for immunoblotting against a-tubulin, total tubulin, or CYLD. (H) Immunoﬂuorescence staining
of microtubule re-growth of EGFP and EGFP–CYLD lentivirus-infected melanoma cells after treatment with nocodazole (50mM) for 10min,
followed by a washout and incubation in fresh culture medium at 371C for 10, 30, or 120min. (I) EGFP or EGFP–CYLD lentivirus-infected
melanoma cells were used to analyse the levels of acetylated a-tubulin and total tubulin in untreated cells or cells treated with nocodazole
(50mM) for 10min followed by a washout and incubation in fresh culture medium at 371C for 10, 30, or 120min before cell lysis. *Po0.05.
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sharp contrast, already 1mM nocodazole induced partial
depolymerisation of MT ﬁbres in EGFP-expressing cells and
5mM nocodazole was sufﬁcient to induce complete depoly-
merisation (Supplementary Figure S3A). Furthermore, treat-
ment with 1mM nocodazole did not change the level of
acetylated tubulin in EGFP–CYLD-expressing melanoma
cells (Supplementary Figure S3B), while treatment with
50mM of nocodazole resulted in almost complete deacetyla-
tion of a-tubulin (Supplementary Figure S3B). These results
indicate that CYLD stabilizes the MT network and protects
the MT network from nocodazole-induced depolymerisation.
CYLD binding to HDAC6 increases a-tubulin acetylation
To analyse whether CYLD regulates tubulin acetylation by
inhibiting HDAC6, we treated keratinocytes and melanoma
cells with different HDAC inhibitors: tubacin, a small-mole-
cule inhibitor of HDAC6; trichostatin-A (TSA), a chemical
inhibitor of class-I and II HDACs, including HDAC6; and
sodium butyrate, a potent inhibitor of class-I and II HDACs
except HDAC6. Sodium butyrate treatment did not affect the
levels of acetylated tubulin either in keratinocytes or in
melanoma cells (Figure 3A and Supplementary Figure S3C).
In addition, TPA stimulation of Cyld
þ/þ keratinocytes led to
an increase in acetylated a-tubulin levels both in the presence
and absence of sodium butyrate (Figure 3A). In contrast,
treatment of Cyld
þ/þ keratinocytes with either TPA or TSA
alone increased acetylated a-tubulin levels to a similar extent,
while simultaneous treatment with both the compounds
failed to induce a synergistic effect (Figure 3B). Moreover,
TSA treatment of Cyld
 /  keratinocytes increased the level of
acetylated a-tubulin, while TPA treatment had no effect
(Figure 3B). A similar effect was observed in keratinocytes
treated with tubacin, which is a selective inhibitor for
HDAC6 (Figure 3C). Furthermore, TSA or tubacin treat-
ment increased the levels of acetylated a-tubulin in
EGFP-expressing melanoma cells (Figure 3D and E), while
treatment of EGFP–CYLD-expressing melanoma cells with TSA
or tubacin failed to increase the levels of acetylated a-tubulin
(Figure 3D and E). Taken together, these ﬁndings suggest that
CYLD, TSA, and tubacin act within the same pathway
to inhibit HDAC6, which results in elevated levels of
acetylated a-tubulin.
Next we investigated whether levels of acetylated tubulin
regulate the subcellular localization of CYLD. To analyse this,
we inhibited HDAC6 in Cyld
þ/þ keratinocytes using TSA or
by downregulating HDAC6 using siRNA. In the absence of
TSA, CYLD localized throughout the cytoplasm (Figure 3F),
while in the presence of TSA or in HDAC6-depleted cells,
the levels of acetylated tubulin increased and CYLD trans-
located to the perinuclear region where it strongly colocalized
with acetylated MTs (Figure 3F and Supplementary
Figure S3D). TPA treatment of HDAC6-depleted cells induced
a similar affect as HDAC6 siRNA alone (Supplementary
Figure S3D). In addition, treatment of keratinocytes with
TSA caused an increase in the interaction of CYLD with
tubulin as compared with that in untreated cells
(Supplementary Figure S3E).
Since CYLD regulates tumour cell proliferation through
direct association with Bcl-3, which in turn inhibits the
nuclear translocation and activity of Bcl-3 (Massoumi et al,
2006), we investigated whether intact MTs are required for
this interaction. As expected, TPA induced interaction of
CYLD with Bcl-3, while this interaction (Figure 3G), as well
as perinuclear localization of CYLD (Supplementary Figure
S4A), was prevented in the presence of nocodazole.
Furthermore, TSA together with TPA, but not in combination
with nocodazole, was able to rescue this interaction
(Figure 3G). However, TSA treatment or HDAC6 depletion
alone did not induce interaction of CYLD with Bcl-3 (Figure
3G and H).These results suggest that inhibition of HDAC6 and
subsequent accumulation of acetylated MTs facilitates the
translocation of CYLD to the perinuclear region, while bind-
ing to Bcl-3 requires both an intact network of acetylated MTs
and an additional signal induced by TPA.
Association of CYLD and HDAC6 in the presence of TPA
To investigate how CYLD regulates HDCA6 function we
analysed whether CYLD regulates the expression of HDAC6.
Western blot analyses excluded reduced HDAC6 expression
as the cause for diminished HDAC6 function in keratinocytes
or melanoma cell lines (Figure 4A and Supplementary Figure
S4B). Furthermore, similar levels of HDAC6 were found in
nuclear and cytoplasmic extracts from TPA-treated Cyld
þ/þ
and Cyld
 /  keratinocytes, as well as from melanoma cells
before and after EGFP–CYLD transduction (Figure 4A and
Supplementary Figure S4B), indicating that CYLD does not
interfere with the subcellular distribution of HDAC6. We also
analysed SIRT2, another a-tubulin deacetylase, and did not
detect SIRT expression in keratinocytes (data not shown),
suggesting that HDAC6 is the major a-tubulin deacetylase in
keratinocytes.
To analyse whether CYLD directly inﬂuences HDAC6
activity, we ﬁrst performed co-immunoprecipitation and im-
munoﬂuorescence experiments using primary keratinocytes.
We observed both co-precipitation (Figure 4B) and colocali-
zation (Figure 4C) of the proteins after TPA treatment,
indicating that they form a protein complex in response to
CYLD activation. The interaction between CYLD and HDAC6
was retained in the presence of nocodazole (Figure 4B),
indicating that the interaction between CYLD and HDAC6
does not require intact MTs. Similarly, HDAC6 co-precipitated
with EGFP–CYLD in melanoma cells, and this interaction was
also retained in the presence of nocodazole (Supplementary
Figure S4C). Furthermore, FLAG pull-down assays with a
series of in vitro translated, FLAG-tagged CYLD-deletion
mutants (Supplementary Figure S2B) showed that the N-
terminal region of CYLD (CYLD
1–212) harboured the ability
to interact with puriﬁed HDAC6 protein (Figure 4D).
To deﬁne which domain(s) in HDAC6 is required for the
interaction with CYLD, a series of HA-tagged HDAC6-deletion
mutants (Zhang et al, 2003) were transiently transfected
together with full-length, FLAG-tagged CYLD into HeLa
cells. FLAG pull-down assays of CYLD demonstrated that
the deletion mutants containing the HDAC6 domain DD1 or
DD2 interacted with CYLD (Figure 4E). To conﬁrm this
interaction we expressed recombinant GST–HDAC6, His–
CYLD, and GST alone as control (Supplementary Figure
S5A). HDAC6 co-precipitated with His–CYLD-bound Ni–
NTA agarose, indicating association of these two proteins
(Figure 4F). Furthermore, GST pull-down assays using the
N-terminal region of CYLD (GST–CYLD
1–212) and the puriﬁed
form of His-tagged, full-length HDAC6 conﬁrmed an interac-
tion between CYLD and HDAC6 (Figure 4G).
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domains
As it was shown earlier that DD1 and DD2 are critical for the
catalytic activity of HDAC6 (Zhang et al, 2006), we hypothe-
sized that binding of CYLD to these domains leads to HDAC6
inactivation. To test this hypothesis, we performed in vitro
tubulin deacetylation assays. We incubated endogenous
HDAC6 and/or EGFP–CYLD immunoprecipitates from
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Figure 3 CYLD inhibits the activity of HDAC6 and tubulin deacetylation. (A) Analysis of the levels (left panels) and quantiﬁcation (right panel) of
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 /  keratinocytes treated with 1mM sodium butyrate (4h) before stimulation with 100nM
TPA (30min). (B) Analysis of the levels (left panels) and quantiﬁcation (right panel) of acetylated a-tubulin and total tubulin in Cyld
þ/þ and Cyld
 / 
keratinocytes treated with 0.3mM TSA (60min) before stimulation with 100nM TPA (30min). (C) Analysis of the levels of acetylated a-tubulin and total
tubulin in Cyld
þ/þ and Cyld
 /  keratinocytes treated with 2mM tubacin (4h) before stimulation with 100nM TPA (30min). (D) Analysis of the levels
(left panels) and quantiﬁcation (right panel) of acetylated a-tubulin and total tubulin in untreated or TSA (0.3 or 5mM for 60min)-treated, EGFP or
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4h)-treated, EGFP or EGFP–CYLD lentivirus-infected melanoma cells. (F) The confocal plane of primary mouse keratinocytes untreated or treated with
0.3mM TSA (15min) and stained for acetylated a-tubulin (red) and CYLD (green). (G) Untreated, TPA- (100nM for 30min), nocodazole- (10mMf o r
60min), or TSA (0.3mMf o r6 0 m i n ) - t r e a t e dCyld
þ/þ keratinocytes immunoprecipitated with antibodies against Bcl-3 and immunoblotted against
CYLD. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation. (H) Cyld
þ/þ keratinocytes were transiently transfected
with control or HDAC6 siRNA (24h) in the absence or presence of TPA (100nM for 30min), followed by immunoprecipitation of endogenous Bcl-3 and
immunoblotting against CYLD. The lysate shows equal amount of protein used for immunoprecipitation and knockdown efﬁciency of HDAC6. *Po0.05.
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MAP-enriched polymerised MTs puriﬁed from bovine brain.
Whereas HDAC6 alone induced deacetylation of a-tubulin,
CYLD or TSA treatment could maintain acetylated a-tubulin
even in the presence of HDAC6 (Figure 5A). To conﬁrm the
speciﬁcity of this effect, we transiently transfected COS cells
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immunoblotting against HDAC6 and CYLD untreated, TPA- (100nM for 30min) and/or nocodazole (10mMf o r6 0 m i n ) - t r e a t e dCyld
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with FLAG-tagged, wild-type or different deletion mutants of CYLD, incubated for 24h, lysed, immunoprecipitated using a-FLAG M2 agarose beads,
and immunoblotted against endogenous HDAC6 or FLAG. The lysate (lower panel) shows equal amount of protein used for immunoprecipitation.
(E) HeLa cells were transiently transfected with HA-tagged, full-length or different deletion mutants of HDAC6 and FLAG-tagged, full-length CYLD.
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1–212 protein was incubated with His–HDAC6 in vitro
for 30min followed by GST pull down using glutathione–agarose beads. The complex was recovered from the beads and analysed by
immunoblotting against His to detect His–HDAC6 or GST to detect GST–CYLD
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cDNA. The polymerised MTs were then incubated with CYLD
and/or HDAC6 immunoprecipitates after peptide elution. We
found a direct correlation between the levels of CYLD and
acetylated a-tubulin in vitro (Figure 5B). To identify the
domain of CYLD responsible for inhibition of HDAC6, we
transiently transfected COS cells with different fragments of
CYLD (Supplementary Figure S2B) or HDAC6. The poly-
merised MTs were then incubated with immunoprecipitates
of these fragments together with HDAC6. As expected, only
the CYLD
1–212 fragment, which mediates the association of
CYLD with HDAC6 (Figure 4D), was able to inhibit HDAC6
activity and subsequent a-tubulin deacetylation (Figure 5C).
Next we tested whether TPA-mediated CYLD activation
inhibits HDAC6 activity by regulating its interaction with
tubulin. To this end, we immunoprecipitated HDAC6 from
Cyld
þ/þ and Cyld
 /  keratinocytes and found that TPA
treatment, which was found to induce the interaction of
CYLD and HDAC6, did not affect the association of HDAC6
with a-tubulin (Figure 5D). Similarly, EGFP–CYLD did not
affect the association of HDAC6 with a-tubulin in the mela-
noma cells (Supplementary Figure S5B).
If loss of CYLD was directly responsible for elevated
HDAC6 activity and increased deacetylation of a-tubulin,
siRNA-mediated depletion of HDAC6 in EGFP-expressing
melanoma cells or Cyld
 /  keratinocytes should restore a-
tubulin acetylation. In line with this hypothesis, the levels of
acetylated a-tubulin increased in melanoma cells upon
HDAC6 depletion (Figure 5E). Furthermore, HDAC6-depleted
Cyld
 /  keratinocytes showed signiﬁcant increase in a-tubu-
lin acetylation irrespective of whether they were untreated or
treated with TPA (Figure 5F).
Delay in the G1/S-phase of the cell cycle and cytokinesis
induced by CYLD
To determine whether CYLD, through its effects on MTs,
can regulate the duration of the cell cycle, we used serum
starvation in combination with contact inhibition to arrest
keratinocytes in G1-phase and nocodazole treatment to
synchronize melanoma cells in G2/M-phase, and then ana-
lysed cell-cycle progression using ﬂow cytometry
(Supplementary Figures S6 and 7). The release of synchro-
nized, TPA-treated keratinocytes caused a delay in G1-to-S
phase transition in Cyld
þ/þ but not in Cyld
 /  keratinocytes
(Figure 6A and Supplementary Figure S6). Similarly, release
of synchronized, nocodazole-treated melanoma cells
revealed a signiﬁcant delay in G1-to-S phase progression
and an accumulation in S-phase of EGFP–CYLD-expressing
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30min) and immunoblotting against tubulin and HDAC6 in the absence or presence of TPA (100nM for 30min). The lysate (lower panel) shows
equal amount of protein used for immunoprecipitation. (E) Immunoblot analysis of HDAC6, acetylated a-tubulin, and total tubulin in EGFP- or
EGFP–CYLD-expressing melanoma cells before or after 24h of transient transfection with HDAC6 siRNAs (0.2mM). (F) Immunoblot analysis of
HDAC6, acetylated a-tubulin, and total tubulin in untreated or TPA (100nM for 30min)-treated Cyld
 /  keratinocytes before or after transient
transfection with HDAC6 siRNAs.
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(Figure 6B and Supplementary Figure S7). To further corro-
borate this ﬁnding, we performed BrdU pulse labelling of
TPA-stimulated keratinocytes as well as melanoma cells. TPA-
stimulated Cyld
þ/þ keratinocytes and EGFP–CYLD-expres-
sing melanoma cells showed reduced levels of BrdU-positive
nuclei as an indication of delayed S-phase progression in the
presence of activated CYLD (Figure 6C and D). To exclude the
possibility that the delay in the G1/S-phase transition in
CYLD-expressing cells is due to differences in mitosis, we
quantiﬁed mitotic intervals by live-cell imaging. The experi-
ments revealed that EGFP–CYLD-expressing melanoma cells
and EGFP-expressing control cells displayed similar rates of
mitosis (Figure 6E).
We have reported earlier that CYLD decreases the prolif-
eration of keratinocytes (Massoumi et al, 2006) and melano-
ma cells (Massoumi et al, 2009) by retaining Bcl-3 in the
cytoplasm and thereby reducing the expression of cyclin-D1.
Interestingly, depletion of Bcl-3 in EGFP-expressing or control
melanoma cells increased the number of cells in G1-phase
(Figure 6F), while expression of CYLD
1–212 or siRNA-
mediated depletion of HDAC6 had no signiﬁcant effect
(Figure 6F). To further assess whether the catalytic activity
and/or HDAC6 and MT binding of CYLD are necessary to
induce a delay in the cell cycle, we analysed the duration of
the cell cycle in melanoma cells expressing full-length CYLD,
catalytically inactive CYLD
C/S, and a deletion mutant that
lacks the ﬁrst CAP-Gly domains (CYLD
222–956) and does not
bind HDAC6. Full-length CYLD induced a delay in G1/S
transition, whereas the catalytically inactive CYLD
C/S or
CYLD
222–956 had no effect. Together, these results suggest
that both deubiquitinase activity as well as HDAC6 binding
are required for CYLD to regulate the cell cycle (Figure 6G).
It has been suggested earlier that the localization of HDAC6
in the midbody might regulate mitosis by affecting MT
dynamics during cytokinesis (Zhang et al, 2003). This
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necting the two daughter cells contains high levels of acety-
lated MTs (Piperno and Fuller, 1985; Schatten et al, 1988; Chu
and Klymkowsky, 1989). We observed that CYLD localizes to
the midbody during cytokinesis (Figure 7A, upper panels).
The localization of CYLD to the midbody has also previously
been reported for dividing HeLa cells overexpressing CYLD
(Stegmeier et al, 2007). In addition, we observed that CYLD
colocalized with HDAC6 in the midbody of both non-
stimulated and TPA-stimulated primary Cyld
þ/þ keratino-
cytes (Figure 7A, lower panels).
To analyse whether the observed localization of CYLD in
the midbody could affect cytokinesis, we determined the
duration of cytokinesis using live-cell imaging. The experi-
ments revealed no differences in the duration of cytokinesis
in non-stimulated Cyld
þ/þ and Cyld
 /  keratinocytes
(Figure 7B), while treatment of cells with TPA induced a
signiﬁcant delay in cytokinetic rate of Cyld
þ/þ as compared
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Figure 7 The N-terminal part of CYLD induces a delay in the cytokinesis rate. (A) The confocal plane of keratinocytes stained for acetylated
a-tubulin, CYLD, or HDAC6 as indicated. The arrows indicate the localization of CYLD and HDAC6 in the midbody. (B) Duration of cytokinesis
of Cyld
þ/þ and Cyld
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1–212 in the midbody. **Po0.01.
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 /  keratinocytes (Figure 7B). This
phenotype could also be detected in EGFP–CYLD-expressing
melanoma cells as compared with EGFP-expressing control
cells (Figure 7C). Furthermore, the N-terminal but not the
C-terminal domain of CYLD localized to the midbody of
melanoma cells (Figure 7D) and induced a delay in cytokin-
esis (Figure 7C). However, expressing CYLD
1–212-carrying
mutations in the CAP-Gly1 domain (Supplementary Figure
S2B), to disrupt MT binding (Feierbach et al, 1999), failed to
induce a delay in cytokinesis, whereas the catalytically
inactive mutant CYLD
C/S retained this ability (Figure 7C).
Altogether these results indicate that inhibition of Bcl-3
by the deubiquitinase activity of CYLD induces a delay in
the G1/S transition, while the N-terminal domain of CYLD,
which binds MTs and inhibits HDAC6 activity, regulates
the perinuclear localization of CYLD and reduces the rate
of cytokinesis.
Discussion
CYLD is a deubiquitination enzyme, which acts primarily as a
tumour-suppressor gene. Mutations in the CYLD gene were
discovered in patients suffering from cylindromatosis, which
is a benign tumour derived from the cells of the skin (Bignell
et al, 2002). We have recently shown that CYLD expression is
very low in melanoma cells due to transcriptional suppres-
sion by high levels of Snail (Massoumi et al, 2009).
Interestingly, gene mutation studies on cylindroma patients
showed that the known mutations can cause either loss of
expression or expression of C-terminally truncated versions
of CYLD. The C-terminal part of CYLD harbours the UCH
domain, which is responsible for the deubiquitinase activity
of CYLD (Brummelkamp et al, 2003; Kovalenko et al, 2003;
Trompouki et al, 2003; Massoumi et al, 2006). So far, no
cylindroma patients with mutations giving rise to N-terminal
truncations of CYLD have been identiﬁed (Massoumi and
Paus, 2007). It was speculated that this could be due to the
ability of this region to delay tumour growth and thus be
associated with lower disease penetrance. In the present
study we investigated the role of the N-terminal CAP-Gly
domains of CYLD in the growth and proliferation of both
primary and transformed cells derived from the skin.
The N-terminal region of CYLD contains three CAP-Gly
motifs. We found that two of them (CAP-Gly1 and CAP-Gly2)
associated with tubulin and inhibited tubulin deacetylation.
In addition, we found that TPA treatment of Cyld
þ/þ kera-
tinocytes caused redistribution of CYLD and induced its
accumulation in the perinuclear region, which has been
previously shown to be critical in mediating the interaction
with its downstream substrate Bcl-3 (Massoumi et al, 2006).
In addition, TPA treatment lead to a marked increase in the
levels of acetylated MTs in this area, and CYLD was found to
extensively colocalize and associate with acetylated MTs.
These observations suggest that CYLD colocalizes preferen-
tially with acetylated MTs, and that the TPA-mediated in-
crease of acetylated MTs in the perinuclear region might in
fact regulate the translocation of CYLD to this area. This
hypothesis is supported by the observation that inhibition of
tubulin deacetylation by downregulation of HDAC6 or inhibi-
tion of its activity by TSA induced a similar translocation of
CYLD to the perinuclear area where it colocalized with the
abundant acetylated MTs, whereas depolymerisation of MTs
inhibited the translocation.
HDAC6, which has been shown to operate as a a-tubulin-
speciﬁc deacetylase (Hubbert et al, 2002), contains two intact
catalytic domains in the central region of the protein.
Mutations in the catalytic domains or treatment of cells
with the HDAC6 inhibitor TSA abrogates the catalytic activity
(Zhang et al, 2006) and increases the pool of acetylated
tubulin. Several lines of evidence suggest that CYLD regulates
the levels of acetylated tubulin by acting as an endogenous
inhibitor of HDAC6. First, inhibition of HDAC6 by TSA or
tubacin treatment failed to induce an additive effect on
acetylated tubulin in the presence of CYLD, suggesting that
TSA, tubacin, and CYLD act within the same pathway. In
addition, CYLD colocalized with HDAC6 in the perinuclear
region, and the endogenous proteins were found in the same
protein complex. Finally, we observed that CYLD binds to the
catalytic domains of this enzyme and inhibits its tubulin
deacetylase activity in vitro.
What are the functional consequences of CYLD-mediated
inhibition of HDAC6 and the increased levels of acetylated
MTs? We observed that CYLD induces a delay in the G1/S
transition of the cell cycle, both in melanoma cells as well as
in keratinocytes. This is in contrast to an earlier study where
downregulation of CYLD by siRNA in HeLa cells induced a
delay in G2/M transition of the cell cycle (Stegmeier et al,
2007). This discrepancy could be explained by different
functions of CYLD depending on the tissue/cell type in
combination with the requirement of a speciﬁc stimulus
such as TPA and/or by siRNA-mediated downregulation of
CYLD versus complete absence of the protein. We have
previously shown that CYLD, through deubiquitination of
Bcl-3, prevents its nuclear translocation. This in turn inhibits
the transcriptional activity of NF-kB p50/p52 and reduces the
expression of cyclin-D1 (Massoumi et al, 2006). Since
expression of cyclin-D1 is critical for the G1/S transition of
the cell cycle, it is very likely that CYLD regulates the G1/S
transition by inhibiting the expression of cyclin-D1.
Interestingly, depletion of HDAC6 or expression of the
N-terminal domain of CYLD, which interacts and inhibits
HDAC6, was unable to increase the number of G1-phase cells,
suggesting that the inactivation of HDAC6 and hyperacetyla-
tion of MTs alone is not the cause of the G1/S cell-cycle delay.
This is supported by the ﬁnding that depletion of HDAC6 was
not sufﬁcient to induce the interaction of CYLD with Bcl-3,
but TPA-mediated activation of CYLD is additionally required.
However, a deletion mutant of CYLD, which is unable to bind
HDAC6, but contains an intact catalytical domain, did not
induce a delay in cytokinesis. Thus, we suggest that the
association of CYLD with acetylated MTs leads to its peri-
nuclear accumulation, which when followed by an additional
TPA-mediated signal prevents nuclear accumulation of Bcl-3,
leading to decreased cyclin-D1 expression and delay in
G1/S transition. It is interesting to note that a direct interac-
tion between HDAC6 and Bcl-3 has been reported earlier
in other cell types (Viatour et al, 2004), suggesting that
formation of these protein complexes could be spatiotempo-
rally linked.
The ﬁnding that CYLD colocalizes with HDAC6 in the
midbody between bundles of acetylated MTs in both kerati-
nocytes and melanoma cells, prompted us to investigate the
rate of cytokinesis in these cells. Although CYLD is present in
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TPA treatment, CYLD was found to induce a delay in cytokin-
esis only after TPA treatment. We could also detect a reduc-
tion in the rate of cytokinesis in melanoma cells expressing
EGFP–CYLD, and in line with the effect of EGFP–CYLD on
G1/S-phase transition of melanoma cells, also this effect did
not require an additional stimulus. Interestingly, the N-term-
inal domain, which binds to tubulin and HDAC6, but not the
UCH-containing C-terminal domain of CYLD, was able to
localize to the midbody and induce a delay in cytokinesis.
In addition, mutations in the CAP-Gly1 domain, which impair
MT binding, abolished this effect, whereas a catalytically
inactive CYLD had no effect. This suggests that localization
of CYLD to the midbody is important for its effect on
cytokinesis, whereas deubiquitinase activity of CYLD is not
required for this function. The reason why CYLD does not
have an effect on cytokinesis in the absence of TPA treatment
in the primary keratinocytes, despite its presence in the
midbody, is unclear. It is possible that TPA induces additional
changes in CYLD itself or in unidentiﬁed inhibitory proteins,
which are necessary for the function of CYLD. This hypoth-
esis is supported by our ﬁnding that CYLD is unable to bind
HDAC6 in the absence of TPA treatment. The molecular
details of this process need to be addressed in future studies.
The precise role of acetylated MTs and tubulin acetylation
in the regulation of the cell cycle and mitosis is not under-
stood, although it is known that the cytoplasmic bridge
connecting the two daughter cells during cytokinesis is highly
enriched in acetylated tubulin in many cell types (Piperno
and Fuller, 1985; Schatten et al, 1988; Chu and Klymkowsky,
1989). Previous studies have shown that the degree of tubulin
acetylation reﬂects the dynamics of MTs (reviewed by
Westermann and Weber, 2003), and that stable, nocodazole-
resistant MTs are essential for recruitment of myosin-II and
RhoA to allow contraction of the cleavage furrow during
cytokinesis (Bement et al, 2005). In addition, tubulin acetyla-
tion itself regulates the recruitment and dynamics of the MT
motor protein kinesin-1, which regulates long-distance intra-
cellular delivery (Reed et al, 2006). Interestingly, HDAC6-
mediated tubulin acetylation was recently shown to regulate
intracellular transport in neurons (Dompierre et al, 2007).
It is, therefore, possible that CYLD, through its effect on
HDAC6 or a direct effect on the MTs, regulates the dynamics
of MTs and/or recruitment of proteins required for successful
execution of cytokinesis. Interestingly, other tumour suppres-
sors have previously been shown to use tubulin acetylation
as mechanism to regulate the cell cycle. Loss of the tumour
suppressor LAPSER1, which also localizes to the midbody,
leads to a decrease in acetylated tubulin accompanied by an
increase in the rate of cytokinesis and proliferation (Sudo and
Maru, 2007). The tumour suppressor CHFR also localizes to
the midbody and regulates the levels of acetylated a-tubulin
in the mitotic spindle during cytokinesis (Privette et al, 2008).
Taken together, CYLD simultaneously employs two func-
tional properties to negatively regulate the proliferation rates
of keratinocytes and melanoma cells. The abnormal cell-cycle
progression through G1 phases and cytokinesis are both
hallmarks of cancer cell proliferation. Since many tumour
types and cancer cell lines lack or have low CYLD expression
(Hellerbrand et al, 2007; Massoumi et al, 2009), our ﬁndings
provide a mechanistic explanation for their elevated prolif-
eration rates.
Materials and methods
Cell culture and transfection
The melanoma cell lines Mel Im and Mel Juso were derived from
metastases of malignant melanomas (Rothhammer et al, 2005).
Isolation and culture of primary normal human epidermal
melanocytes (NHEM) were performed as previously described by
Rothhammer et al (2005). Primary keratinocytes were isolated from
back skin of 8-week-old mice and cultured as described by Romero
et al (1999).
Viral infections
Stable expression of EGFP, EGFP–CYLD, HA–CYLD, and HA–
CYLD
C/S in melanoma cells was achieved by lentiviral gene transfer.
In brief, CMV promoter-driven lentiviral constructs were obtained
by cloning EGFP, EGFP–CYLD, HA–CYLD, and HA–CYLD
C/S into a
lentiviral vector (p156rrlsinPPTCMV). The titre of the lentiviral
particles was determined by measuring the amount of HIV p24 gag
antigen by ELISA (Alliance; NEN). To calculate the amount of
infectious units (IU), the p24 titre was correlated to the biological
activity of a similar virus carrying a green-ﬂuorescent protein (GFP)
cassette by using serial dilutions of the GFP virus to transduce 293T
cells (1ng of p24¼1 10
5 IU). Melanoma cells were infected with
1 10
5 IU for 24h using the calcium phosphate method and the
medium was replaced two times before the cells were used in
different assays.
Transient transfections
CYLD truncation mutants were ampliﬁed by PCR and cloned into
CMV promoter-driven pCS2 construct. The CAP-Gly1 mutant was
generated by mutating the GFTDG sequence in the CYLD
1–212
construct into AFADA, Transient transfection assays were per-
formed in six-well plates at 80% conﬂuence using the Polyfect
transfection reagent (Qiagen) and 1.0 or 3.0mg of DNA, and 10 or
30ml of Polyfect were suspended in cell growth medium containing
no serum or antibiotics. The mixture was incubated for 10min at
room temperature to allow complex formation. Cells were washed
once with phosphate-buffered saline (PBS) before adding 1ml of
fresh cell growth medium containing serum and antibiotics, after
which the transfection mixture was added to the cells. Experiments
were performed 24 or 48h after transfection. All transfection assays
were repeated three times and performed in triplicates.
Depletion of Bcl-3 and HDAC6
SiRNAs (control, Bcl-3, and HDAC6) were purchased from Santa
Cruz. SiRNA duplexes (0.2mM) were mixed with Lipofectamine
(Invitrogen) transfection reagent (10ml) and incubated at room
temperature for 15min. For each transfection, 0.8ml siRNA
transfection mixture was added to 80% conﬂuent cells in six-well
tissue culture plate two times within 24h. Experiments were
performed 24h after transfection.
Immunoblots and immunoprecipitation
For immunobloting, lysates from whole cells or cytosolic and
nuclear extracts were resolved in SDS±PAGE gels and transferred to
PVDF membranes, followed by incubation with primary antibodies
anti-total a-tubulin; anti-tyrosinated a-tubulin; anti-acetylated
a-tubulin; anti HA and a-FLAG M2 agarose beads (all from Sigma);
anti-rat monoclonal tubulin (from Abcam); anti-HDAC6; anti-lamin-
B and anti-Bcl-3 (from Santa Cruz). Rabbit polyclonal Cyld antibody
has been described earlier (Massoumi et al, 2006).
For immunoprecipitations lysates were obtained from untreated
or TPA-treated (100nM) primary keratinocytes, human primary
melanocytes (NHEM), or human malignant melanoma cell lines.
The samples were centrifuged at 10000g for 20min. For anti-CYLD
immunoprecipitation the lysates were pre-cleared for 30min at 41C.
The protein content was determined and compensated for equal
content in all supernatants and used for immunoprecipitation.
FLAG immunoprecipitation was performed by using anti-FLAG M2
afﬁnity gel and eluted using FLAG-peptide purchased from Sigma.
HA immunoprecipitation was performed by using anti-HA antibody
and eluted using HA-peptide purchased from Sigma. EGFP
immunoprecipitation was performed by using anti-GFP microBeads
purchased from Miltenyi Biotech and used according to the
manufacturer’s instructions. Immunoblots were developed with
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manufacturer’s instructions.
Immunoﬂuorescence
Cells were grown on glass coverslips and ﬁxed with ice-cold 100%
methanol. After rehydration with PBS, unspeciﬁc binding was
blocked with PBS containing 3% bovine serum albumin (BSA) and
5% goat serum, followed by incubation with primary antibodies
against CYLD (Massoumi et al, 2006), tyrosinated tubulin (Chemi-
con), FLAG (Sigma), acetylated tubulin (Sigma), and HDAC6 (Santa
Cruz), and ﬂuorescence labelled secondary antibodies (Alexa,
Invitrogen). Finally, the coverslips were washed and mounted on
glass slides using Vectashield (Vector Laboratories). The ﬂuores-
cence images were collected by laser-scanning confocal microscopy
(DMIRE2; Leica) using Leica Confocal Software version 2.5 Build
1227 with  100 oil-immersion objectives. All images were
collected at room temperature.
Colocalization was measured by linescans from immunoﬂuores-
cence images using the MetaMorph software.
In vitro tubulin deacetylation assay
Tubulin deacetylation assays were performed as described earlier
(Hubbert et al, 2002). Brieﬂy, MAP-enriched bovine tubulin
(cytoskeleton) was polymerised into microtubules in the absence
of paclitaxel or glycerol by incubation for 30min at 351C. The
polymerised microtubules were incubated at 371C for 2h with HA–
HDAC6 and/or FLAG–CYLD immunoprecipitates (after elution
using HA respective FLAG peptide; Sigma) in the absence or
presence of TSA (0.5mM). Samples were then placed on ice for
15min. The supernatant was subsequently collected by centrifuga-
tion and analysed by immunoblotting with antibodies against
acetylated tubulin and total tubulin.
Flow cytometry and BrdU labelling
Malignant melanoma cells were synchronized by treatment with
100ng/ml nocodazole for 16h. Primary keratinocytes were syn-
chronized by a combination of contact inhibition and serum
starvation for 24h, after which they were released into complete
growth medium containing 1mM TPA. After release the cells were
harvested at the indicated time points and ﬁxed with 70% ethanol.
Cells were then stained with propidium iodide and analysed by ﬂow
cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NY,
USA) using FlowJo software (Tree Star Inc., Ashland, OR, USA).
BrdU pulse labelling was performed by arresting cells as
described above. After release, the cells were exposed to BrdU
(10mM) for 12 or 24h. The cells were then ﬁxed with 4%
paraformaldehyde and subsequently with 100% methanol. DNA
was denatured using 1.5M HCl and BrdU labelling was detected
using anti-BrdU antibodies (Sigma) and ﬂuorescent secondary
antibodies.
Quantiﬁcation of mitotic phases and cytokinesis
Malignant melanoma cells were plated on plastic culture dishes and
synchronized using a double thymidine block. Brieﬂy, cells were
treated with 2mM thymidine for 19h. After a 5-h release in
complete culture medium, the cells were treated with thymidine for
another 16h. After release, images of live cells were recorded with a
Zeiss Axiovert 200M (Zeiss, Germany) with a cooled CCD camera
(Roper Scientiﬁc, Princeton, NJ, USA). Image acquisition was
performed with the MetaMorph software (Molecular Devices,
Downington, PA, USA). For quantiﬁcation of mitotic intervals, the
duration of mitotic phases were deﬁned as follows: prometaphase,
from disassembly of nuclear membrane and nucleoli to equatorial
arrangement of chromatin; metaphase, from the beginning to the end
of equatorial arrangement of chromatin; anaphase, from the start of
sister chromatid separation to reformation of nuclear envelopes and
nucleoli; telophase, from the start of nuclear envelope and nucleolar
reformation to formation of two daughter cells.
For quantiﬁcation of cytokinesis cells were plated on plastic
culture dishes in complete culture medium and stimulated with
100nM TPA, when indicated. Images of live cells were recorded as
described above. The duration of cytokinesis was quantiﬁed from
the formation of two daughter cells to abscission.
Statistical analysis
Data are presented as mean±s.e.m. Statistical comparisons were
assessed with analysis of variance (ANOVA) or Student’s t-test after
data were conﬁrmed to fulﬁl the criteria of normal distribution and
equal variance. If overall ANOVA tests were signiﬁcant, we
performed a post hoc Tukey test. Po0.05 was considered signiﬁcant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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